Vliyanie preparatov sul'fonilmocheviny na serdechno-sosudistuyu sistemu
https://doi.org/10.14341/2072-0351-5917
Abstract
Исследование UKPDS показало, что хороший контроль гликемии у больных СД 2 может предотвратить сердечно-сосудистые осложнения. Тем не менее оказалось, что существуют различия между разными вариантами противодиабетического лечения в отношении их кардиопротективного действия. Недавние клинические испытания выявили значительные различия между препаратами сульфонилмочевины разных поколений в отношении их влияния на развитие сердечно-сосудистых заболеваний. Защитные свойства препаратов нового поколения, таких как гликлазид МВ, связывают как с их антиатерогенным, антитромботическим и антиоксидантным эффектами, так и с отсутствием влияния на ишемическое прекондиционирование.
References
1. Bell DS. Stroke in the diabetic patient. Diabetes Care. 1994;17:213-219.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14-S21.
3. Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care. 1992;15:1141- 1155.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
5. Feener EP, Dzau VJ. Pathogenesis of cardiovascular disease in diabetes. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ, eds. Joslin's Diabetes Mellitus. 14 ed. Philadelphia, Pa: Lippincott, WIlliams, and Wilkins; 2005:867-883.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-S36.
8. IDF Clinical Guidelines Task Force. Global Guidelines for Type 2 Diabetes. 2005. Brussels, Belgium: International Diabetes Federation.
9. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31:950-956.
10. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
11. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
13. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439-446.
14. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531-537.
15. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994;90:700-705.
16. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006. In press.
17. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244-2248.
18. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate- sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000;49:3-6.
19. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther. 2004;18:113-119.
20. Loubani M, Fowler A, Standen NB, Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol. 2005;515:142-149.
21. Fu ZZ, Yan T, Chen YJ, Sang JQ. Thromboxane/prostacyclin balance in type II diabetes: gliclazide effects. Metabolism. 1992;41:33-35.
22. Fujitani B, Maeda J, Tsuboi T, et al. Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea-pig platelets. Thromb Res. 1983;21:103-110.
23. Gram J, Jespersen J, Kold A. Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients. Metabolism. 1988;37:937-943.
24. Gram J, Munkvad S, Kold A, et al. Effect of an oral antidiabetic drug (gliclazide) on inhibition of coagulation and fibrinolysis studied in insulintreated patients (type 1). Fibrinolysis. 1989;3:153-158.
25. Gram J, Kold A, Jespersen J. Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide). J Intern Med. 1989;225:241-247.
26. Duhault J, Boulanger M, Longchamp M. Gliclazide and the microvascular system. R Soc Med. 1980;20:9-18.
27. Ceriello A, Bortolotti N, Crescentini A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulindependent diabetic subjects. Eur J Clin Invest. 1998;28:329-333.
28. Mullarky CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173:932-939.
29. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications. 2000;14:201-206.
30. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia. 2003;46:875-891.
31. Scott NA, Jennings PE, Brown J, Belch JJ. Gliclazide: a free radical scavenger. Eur J Pharmacol. 1991;208:175-177.
32. Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima- media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47:1906-1913.
Review
For citations:
Shestakova M.V. Vliyanie preparatov sul'fonilmocheviny na serdechno-sosudistuyu sistemu. Diabetes mellitus. 2007;10(1):54-59. (In Russ.) https://doi.org/10.14341/2072-0351-5917
Views:
6396
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
